The prognostic significance of weight loss in chronic obstructive pulmonary disease-related cachexia: a prospective cohort study

Hoi Yee Kwan1,2‡, Matthew Maddocks3*, Claire M. Nolan2,4, Sarah E. Jones2,4, Suhani Patel2, Ruth E. Barker3, Samantha S.C. Kon2,5, Michael I. Polkey4, Paul Cullinan4 & William D.-C. Man2,4

1Department of Respiratory Medicine, Kowloon Hospital, HKSAR, China, 2Department of Respiratory Medicine, Kowloon Hospital, Kowloon Hospital NHS Foundation Trust, London, UK, 3Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King’s College London, London, UK, 4National Heart and Lung Institute, Imperial College, London, UK, 5Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King’s College London, London, UK

Abstract

Background Cachexia is an important extra-pulmonary manifestation of chronic obstructive pulmonary disease (COPD) presenting as unintentional weight loss and altered body composition. Previous studies have focused on the relative importance of body composition compared with body mass rather than the relative importance of dynamic compared with static measurements. We aimed to determine the prevalence of cachexia and pre-cachexia phenotypes in COPD and examine the associations between cachexia and its component features with all-cause mortality.

Methods We enrolled 1755 consecutive outpatients with stable COPD from two London centres between 2012 and 2017, stratified according to European Respiratory Society Task Force defined cachexia [unintentional weight loss >5% and low fat-free mass index (FFMI)], pre-cachexia (weight loss >5% but preserved FFMI), or no cachexia. The primary outcome was all-cause mortality. We calculated hazard ratios (HRs) using Cox proportional hazards regression for cachexia classifications (cachexia, pre-cachexia, and no cachexia) and component features (weight loss and FFMI) and mortality, adjusting for age, sex, body mass index, and disease-specific prognostic markers.

Results Prevalence was similar across sexes but increased with worsening Global Initiative for Chronic Obstructive Pulmonary Disease spirometric stage and Medical Research Council dyspnoea score (all P < 0.001). There were 313 (17.8%) deaths over a median (interquartile range) follow-up duration 1089 (547–1704) days. Both cachexia [HR 1.98 (95% CI: 1.31–2.99), P = 0.002] and pre-cachexia [HR 2.79 (95% CI: 1.48–5.29), P = 0.001] were associated with increased mortality. In multivariable analysis, the unintentional weight loss feature of cachexia was independently associated with mortality [HR 2.16 (95% CI: 1.31–3.08), P < 0.001], whereas low FFMI was not [HR 0.88 (95% CI: 0.64–1.20), P = 0.402]. Sensitivity analyses using body mass index-specific, age-specific, and gender-specific low FFMI values found consistent findings.

Conclusions Despite the low prevalence of cachexia and pre-cachexia, both confer increased mortality risk in COPD, driven by the unintentional weight loss component. Our data suggest that low FFMI without concurrent weight loss may not confer the poor prognosis as previously reported for this group. Weight loss should be regularly monitored in practice and may represent an important target in COPD management. We propose the incorporation of weight monitoring into national and international COPD guidance.

Keywords Body composition; Cachexia; COPD; Mortality; Phenotypes

© 2019 The Authors Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Introduction

Chronic obstructive pulmonary disease (COPD) is a major cause of global morbidity and mortality.\(^5\) Extra-pulmonary manifestations of COPD, such as altered body composition, have long been recognized\(^2\) and represent remediable aspects of the disease\(^6\) that impact on prognosis, reflected by their inclusion within the BODE [body mass index (BMI), airflow obstruction, dyspnoea, and exercise capacity] prognosis index.\(^7\)

Cachexia is a complex syndrome that encompasses multiple manifestations of COPD. The prominent and dynamic feature of cachexia is unintentional weight loss, driven by a variable combination of reduced food intake and metabolic disturbance.\(^8,9\) The multi-faceted nature of cachexia has led to difficulties defining it for study. A consensus definition from the Cachexia Consensus Working Group requires the presence of ≥5% weight loss in the previous year or a BMI <20 kg/m\(^2\) plus ≥3 of five markers of metabolic disturbance [decreased muscle strength, fatigue, anorexia, low fat-free mass index (FFMI), or abnormal biochemistry] to diagnose cachexia.\(^8\) Similarly, diagnosis of a pre-cachexia state defined by the European Society of Clinical Nutrition and Metabolism Special Interest Group on cachexia–anorexia requires assessment of weight loss (≤5% in the previous 6 months) plus markers of anorexia and metabolic disturbance.\(^9,10\) Whilst these detailed assessments help to delineate cachexia from other nutritional disorders, they are difficult to apply in large epidemiological studies. Indeed, to our knowledge, the Cachexia Consensus Working Group definition has not been applied to a COPD cohort in the decade since its publication.\(^8\)

The European Respiratory Society (ERS) Task Force on nutritional assessment and therapy in COPD recently provided expert-derived pragmatic definitions for different metabolic phenotypes, using practical assessment modalities that can be more readily applied in practice.\(^11\) The Task Force focused on presenting features of cachexia, rather than the underlying pathophysiology, and defined cachexia as ‘unintentional weight loss >5% in six months and fat-free mass index (FFMI) <17kg/m\(^2\) in males and <15kg/m\(^2\) in females’.\(^11\) The FFMI cut-offs relate to the 10th percentile of the overall population, which have been associated with survival in COPD.\(^5\) The Task Force also defined a pre-cachexia phenotype as ‘unintentional weight loss >5% in six months’ but with preserved FFMI to identify an at-risk group for whom interventions might prevent cachexia or delay its onset.\(^5\)

A prospective validation of these practical definitions is lacking in COPD. Moreover, whilst previous studies in COPD have demonstrated the additional prognostic importance of baseline body composition compared with BMI alone,\(^3,5\) the relative importance of dynamic changes in body composition (e.g. weight loss) compared with static measures has not been examined outside of small historical cohorts with very advanced COPD and respiratory failure.\(^12\)

We therefore aimed to determine the prevalence of cachexia and pre-cachexia in patients with stable COPD, to characterize the cachexia phenotype, and to examine the associations between cachexia and its component features with mortality. We hypothesized that mortality risk would be increased in the presence of cachexia as compared with the presence of unintentional weight loss or low FFMI alone.

Materials and methods

Study design and population

For this prospective cohort study, a consecutive series of patients attending outpatient respiratory, pulmonary rehabilitation, and community assessment clinics in northwest London, UK, were approached between January 2012 and May 2017. Eligible patients were aged 40 years or above, with a ratio of forced expiratory volume in 1 s (FEV\(_1\)) to forced vital capacity of less than 0.7 and a physician diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines.\(^13\) Exclusion criteria were any condition that precluded an incremental exercise test on grounds of safety (e.g. unstable cardiac disease) or bioelectrical impedance analysis (e.g. an implanted pacemaker or defibrillator), a co-morbid progressive neuromuscular disorder, a current cancer diagnosis, or an exacerbation of COPD within the preceding month that required a change in medication. The study was approved by the West London (11/H0707/2) and London Camberwell St Giles (11/LO/1780) Research Ethics Committees, London, UK. All participants provided informed consent.

Cachexia classification

Unintentional weight loss was assessed using current weight (MC-780, Tanita, Illinois, USA) and a structured clinical history following British Association For Parenteral And Enteral Nutrition (BAPEN) guidance.\(^14\) Patients were asked if they ‘had lost weight in the last six months?’ that was unplanned, and if so, ‘how much did you weigh six months ago?’ from which weight loss was calculated as a percentage.\(^14\) If patients reported weight loss but could not provide a prior weight, they were asked if clothes and/or jewellery had become loose, taken as significant weight loss.\(^15\) Fat-free mass (FFM, kg) was estimated using whole body bioelectrical impedance analysis (Quadscan 4000, Bodystat, Isle of Man, UK) and a disease-specific equation,\(^15\) expressed as fat-free mass index (FFMI = FFM/height\(^2\) in kg/m\(^2\)). Using the ERS Task Force on nutritional assessment in COPD definitions,\(^11\) patients reporting unintentional weight loss of >5% over the preceding 6 months and with a FFMI <17 kg/m\(^2\) for men and <15 kg/m\(^2\) for women were classified as having cachexia. Patients reporting
unintentional weight loss of >5% over the preceding 6 months but with a preserved FFMI were classified as having pre-cachexia. As per usual local practice, those classified as having pre-cachexia or cachexia were provided with an information leaflet\(^\text{16}\) with dietetic referral based on clinical judgement. Patients with no cachexia (no unintentional weight loss) were further classified into those with low or preserved FFMI. For a sensitivity analysis, we reclassified low FFMI using BMI-specific, age-specific, and gender-specific cut-offs derived from the UK Biobank.\(^\text{17}\)

### Outcomes

All-cause mortality, our primary outcome, was assessed over a 6-year observation window (2012–17). Deaths were recorded up to 29 August 2017 using data retrieved from the UK National Health Service ‘spine’, maintained by the NHS Care Records Service. Age, sex, and ethnic origin were recorded from medical records. Other outcomes assessed at study enrolment were FEV\(_1\) recorded from medical records. Other outcomes assessed at enrolment were FEV\(_1\) using spirometry, functional exercise capacity using the incremental shuttle walk (ISW) test,\(^\text{18}\) respiratory disability using the Medical Research Council (MRC) dyspnoea score, and health-related quality of life assessed by the COPD Assessment Test.\(^\text{19}\)

### Statistical analysis

The recruitment target was 1700 participants based on the precision to which cachexia prevalence could be estimated: ±2.5% with a large sample normal approximation (nQuery Advisor V.6.0) and previous studies that identified modified mortality risk from altered body composition parameters. The prevalence of cachexia, with 95% confidence interval (95% CI) calculated using Wilson’s method, was determined overall and compared across sex, age, GOLD spirometric stage, and MRC dyspnoea score categories using \(\chi^2\) for trend. Baseline clinical characteristics were compared across groups through one-way analysis of variance or Kruskal–Wallis tests with \(\chi^2\), independent \(t\)-test, Mann–Whitney \(U\)-tests for pairwise comparisons.

Survival was plotted using Kaplan–Meier curves, and the log–rank test was used to compare survival curves according to cachexia classifications (cachexia, pre-cachexia, and no cachexia) and component features (unintentional weight loss and low FFMI). After censoring and proportionality assumptions had been satisfied, associations with mortality were investigated using Cox proportional hazards regression models. In univariate separate models, either cachexia classification or component features were entered as independent variables along with the covariates age, sex, smoking status, Charlson co-morbidity index, exacerbations in the previous year, BMI category, FEV\(_1\) per cent predicted, MRC dyspnoea score, and ISW distance as reported predictors of mortality in COPD. After checking for collinearity (\(r < 0.75\)), all variables significantly associated with mortality (\(P < 0.10\)) were considered in a multivariate model. Hazard ratios (HRs) with 95% CI were estimated. Analyses were performed using SPSS (version 22, IBM, New York), and \(P\) values less than 0.05 were considered significant.

### Results

#### Patient characteristics

Of the 2250 consecutive patients approached, 1755 (78%) were enrolled. Participants had a mean (standard deviation) age of 70 (10) years, FEV\(_1\) 48.6 (19.5) % predicted, and BMI 27.8 (6.7) kg/m\(^2\) (Table 1). The most prevalent co-morbidities were diabetes, peripheral vascular disease, and congestive heart failure, present in 10.5%, 6.7%, and 4.7% of patients, respectively. Overall, the prevalence of cachexia was 4.6% (95% CI: 3.6–5.6), and the prevalence of pre-cachexia was 1.6% (95% CI: 1.0–2.2). The prevalence of cachexia was similar across sexes [male: 4.7% (95% CI: 3.4–6.0); female 4.5% (95% CI: 3.1–6.1)] but increased with worsening GOLD spirometric stage and MRC dyspnoea score (\(P\) for trend <0.001 each).

In addition to the defining characteristics of a low body weight and FFMI, patients with cachexia presented with significantly reduced FEV\(_1\)% predicted and exercise capacity, more exacerbations in the previous year (\(P < 0.001\) each), and a higher level of respiratory-related disability (\(P = 0.005\)) as compared with patients with no cachexia. The groups did not differ statistically with respect to sex distribution, age, smoking history, long-term oxygen therapy use, or health-related quality of life (Table 1). Of patients without cachexia or pre-cachexia, 620/1646 (35.3%) had a low FFMI. Baseline characteristics for this group according to the presence of low or preserved fat-free mass index are presented in the Supporting Information, Table S1.

#### Mortality

We recorded 313 deaths (17.8%) over median (interquartile range) follow-up duration 1089 (547–1704) days. All-cause mortality at the end of the first, second, and third years of study follow-up was 5.3%, 10.3%, and 15.7%, respectively.

Survival was reduced in groups with baseline cachexia and pre-cachexia as compared with the group with no cachexia (both \(P < 0.001\)). In contrast, no difference in survival was observed between groups with baseline cachexia and pre-cachexia (\(P = 0.699\)) (Figure 1). In unvariable analyses, both cachexia (HR 2.50 [95% CI: 1.67–3.75]) and pre-cachexia (HR 2.82 [95% CI: 1.50–5.30]) were associated with mortality, as were advancing age, male sex, lower BMI, lower FEV\(_1\)%
predicted, higher MRC score, and reduced ISW (P < 0.001) (Table 2). In multivariable analysis, both cachexia [adjusted HR 1.98 (95% CI: 1.31–2.99)] and pre-cachexia [adjusted HR 2.79 (95% CI: 1.48–5.29)] remained independent predictors of mortality (Table 2).

Concerning the component features of cachexia, the survival curve for patients with low FFMI but no unintentional weight loss was not significantly different to that of patients with preserved FFMI (P = 0.214). Furthermore, in patients with low FFMI, survival was significantly reduced in patients with unintentional weight loss compared with those with no weight loss (P < 0.001) (Figure 2). In univariable analyses, considering anthropometric and body composition variables, unintentional weight loss [HR 2.58 (95% CI: 1.82–3.66)] and low FFMI [HR 1.30 (95% CI: 1.04–1.63)] were each associated with mortality, as were advancing age, male sex, lower BMI, lower FEV₁%, predicted, higher MRC score, Charlson score, and reduced ISW (P < 0.001) (Table 3). In multivariable analysis, unintentional weight loss remained a significant predictor of mortality [adjusted HR 2.16 (95% CI: 1.51–3.08)], whereas low FFMI did not [adjusted HR 0.88 (95% CI: 0.64–1.20), P = 0.402] (Table 3).

The sensitivity analysis using BMI-specific, age-specific, gender-specific low FFMI values made no meaningful difference to the main finding. Low FFMI did not remain in the multivariable analysis, whereas unintentional weight loss remained a significant predictor of mortality [adjusted HR 2.17 (95% CI: 1.50–3.15)] after adjusting for age, sex, FEV₁% predicted, co-morbidity burden, and ISW distance (Supporting Information, Table S2).

## Discussion

This large prospective cohort study found a prevalence of 4.6% and 1.6% for cachexia and pre-cachexia in outpatients with stable COPD. Patients with these phenotypes had a poorer exercise capacity and more severe respiratory disability as compared with those with no cachexia, including those with a low FFMI alone. Both cachexia and pre-cachexia were
associated with increased mortality risk. However, contrary to our hypothesis, low FFMI did not add prognostic value to unintentional weight loss alone. Our findings underscore the prognostic importance of unintentional weight loss in COPD.

Low body weight per se has consistently been associated with mortality in COPD; indeed, BMI is a component of the BODE index, the best known prognostic index in COPD. However, BMI does not take into account abnormalities of body composition; consequently, the ERS Task Force on nutritional assessment and therapy recommend measures of body composition to distinguish between patients with low and normal fat-free mass. This recommendation is supported by evidence from two large well-characterized cohort studies that demonstrated additional prognostic value of low FFMI for mortality compared with BMI alone.

In line with previous studies, we found reduced FFMI to be associated with increased mortality risk when considered in isolation. However, FFMI was no longer an independent predictor of mortality when unintentional weight loss and other established predictors of poor prognosis were considered in multivariable models.

### Table 2 Cox proportional hazard models for all-cause mortality in patients with COPD according to cachexia status

| Covariate          | Univariate                   | Multivariate                  |
|--------------------|------------------------------|--------------------------------|
|                    | HR   | 95% CI | P value   | Adjusted HR | 95% CI | P value |
| Age                | 1.031| 1.018–1.044 | <0.001     | 1.028       | 1.015–1.042 | <0.001 |
| Sex (male)         | 1.533| 1.213–1.937 | <0.001     | 1.631       | 1.283–2.074 | <0.001 |
| Smoking (current)  | 0.845| 0.628–1.136 | 0.264      | —           | —       | —       |
| FEV1 (% predicted) | 0.983| 0.977–0.990 | <0.001     | 0.984       | 0.997–0.991 | <0.001 |
| MRC dyspnoea score | 1.285| 1.157–1.428 | <0.001     | —           | —       | 0.353   |
| ISW distance       | 0.996| 0.996–0.997 | <0.001     | 0.997       | 0.996–0.998 | <0.001 |
| Previous exacerbation | 1.007 | 0.974–1.042 | 0.664 | — | — | 0.556 |
| Charlson score     | 1.231| 1.119–1.353 | <0.001     | 1.157       | 1.053–1.271 | 0.002   |
| BMI                | Reference | Reference | Reference | Reference | Reference | Reference |
| 18.5–24.99         | 0.748| 0.476–1.177 | 0.210      | — | — | 0.498 |
| 25–29.99           | 0.496| 0.309–0.795 | 0.004      | — | — | 0.117 |
| >30                | 0.546| 0.342–0.872 | 0.011      | — | — | 0.218 |
| No cachexia        | Reference | Reference | Reference | Reference | Reference | Reference |
| Pre-cachexia       | 2.815| 1.496–5.297 | 0.001      | 2.794       | 1.476–5.288 | 0.002   |
| Cachexia           | 2.504| 1.674–3.746 | <0.001     | 1.982       | 1.314–2.989 | 0.001   |

All variables significantly associated with mortality (P < 0.10) in univariate analysis were considered in the multivariate model. BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; HR, hazard ratio; ISW, incremental shuttle walk; MRC, Medical Research Council.
baseline body composition measures but not dynamic changes in weight or muscle mass. Differences in the composition and baseline characteristics of patients may be important, but our data suggest that the previously observed effect of low FFMI on survival may be driven by a subgroup with unintentional weight loss—a factor not assessed in these cohorts but studied historically in small cohorts of patients with very advanced COPD and respiratory failure. All cachexia definitions stress the dynamic nature of the syndrome and require a change in weight over time.\textsuperscript{8,11} Indirect evidence to support our hypothesis is the observation that low FFMI observed in older patients with COPD may be long-standing and insidious and a result of insults earlier in life such as smoking or reduced physical activity. Furthermore, cohort studies have shown that continuing decline in fat-free mass is uncommon in COPD\textemdash;this was corroborated

![Figure 2](image_url) Survival curves for patients with chronic obstructive pulmonary disease classified by fat-free mass index (FFMI) with or without unintentional weight loss. Low FFMI with unintentional weight loss was associated with reduced survival as compared with normal FFMI (\(P < 0.001\)), whereas low FFMI without unintentional weight loss was not (\(P = 0.214\)).

| Number at risk          | Follow-up (days) | Proportion surviving (%) |
|------------------------|------------------|--------------------------|
|                        |                  | 0           | 20           | 40           | 60           | 80           | 100          |
| Normal FFMI            | 1054             | 850         | 631          | 403          | 186          | 54           | 0            |
| Low FFMI without weight loss | 620             | 472         | 274          | 167          | 83           | 28           | 0            |
| Low FFMI with weight loss | 81              | 51          | 34           | 16           | 6            | 1            | 0            |

**Table 3** Cox proportional hazard models for all-cause mortality in patients with COPD according to cachexia constituents

| Covariate                  | Univariate | Multivariate |
|----------------------------|------------|-------------|
|                            | HR         | 95% CI      | \(P\) value | Adjusted HR | 95% CI      | \(P\) value |
| Age                       | 1.031      | 1.018–1.044 | \(<0.001\)  | 1.029       | 1.015–1.042 | \(<0.001\)  |
| Sex (male)                | 1.533      | 1.213–1.937 | \(<0.001\)  | 1.615       | 1.272–2.052 | \(<0.001\)  |
| Smoking (current)         | 0.845      | 0.628–1.136 | \(0.264\)   | —           | —           | —           |
| FEV\(_1\) (% predicted)   | 0.983      | 0.977–0.990 | \(<0.001\)  | 0.984       | 0.978–0.991 | \(<0.001\)  |
| MRC dyspnoea score        | 1.285      | 1.157–1.428 | \(<0.001\)  | —           | —           | —           |
| ISW                       | 0.966      | 0.996–0.997 | \(<0.001\)  | 0.997       | 0.996–0.998 | \(<0.001\)  |
| Previous exacerbation     | 1.007      | 0.974–1.042 | \(0.664\)   | —           | —           | —           |
| Charlson score            | 1.231      | 1.119–1.353 | \(<0.001\)  | 1.156       | 1.053–1.270 | \(0.002\)  |
| BMI                       | Reference  | Reference   | —           | —           | —           | —           |
| \(<18.5\)                 |            |            |             | —           | —           | —           |
| 18.5–24.99                | 0.748      | 0.476–1.177 | \(0.210\)   | —           | —           | —           |
| 25–29.99                  | 0.496      | 0.309–0.795 | \(0.004\)   | —           | —           | —           |
| \(>30\)                   | 0.546      | 0.342–0.872 | \(0.011\)   | —           | —           | —           |
| \(>5\%\) unintentional weight loss | 2.583   | 1.823–3.660 | \(<0.001\)  | 2.160       | 1.515–3.079 | \(<0.001\)  |
| Low FFMI \(^a\)           | 1.300      | 1.038–1.629 | \(0.022\)   | —           | —           | —           |

All variables significantly associated with mortality (\(P < 0.10\)) in univariate analysis were considered in the multivariate model. 95% CI, 95% confidence interval of HR; BMI, body mass index; FEV\(_1\), forced expiratory volume in 1 s; FFMI, fat-free mass index; HR, hazard ratio; ISW, incremental shuttle walk; MRC, Medical Research Council.

\(^a\)Low FFMI defined as FFMI \(<15/17\) kg/m\(^2\) women/men.
by our study, with only 11.5% of patients with low FFMI reporting recent unintentional weight loss. There are potential limitations to our study. First, the prevalence of cachexia in our cohort was lower than previously reported. This is most likely explained by previous studies focusing on cohorts with more advanced COPD, the application of different cachexia criteria, and the increase in body size with obesity. We acknowledge that our population consisted primarily of stable, Caucasian (93%) outpatients, and our findings need to be corroborated in other settings and countries. We hypothesize that the ERS Task Force cut-offs for FFMI may over-estimate or under-estimate the prevalence of cachexia in different ethnic populations. Cachexia may also be more prevalent in specific settings, such as in care or nursing homes or acute hospitals. Second, we assessed unintentional weight loss through clinical history as serial measurements of weight were often not recorded in patient care records. Multiple measures of weight and body composition would have extended our study findings and allowed us to examine the impact of different trajectories on clinical outcome, and we recommended longitudinal assessment in future studies. However, we followed a consensus-recommended systematic process, and patient-reported weight history is reliable and the accepted standard in cancer cachexia. Indeed, viewed from a clinician perspective, the fact that patient-reported observations generated powerful data is reassuring. Third, it has long been observed that weight loss is associated with a particular COPD subtype, namely, the ‘pink puffer’ with emphysema. The majority of our stable outpatient cohort did not have contemporaneous imaging or full lung function measurements to assess the degree of emphysema, and so we are unable to exclude this as a confounding factor. Finally, unintentional weight loss may have been a manifestation of cancer, which we cannot rule out without cause-specific mortality data. However, those with a current cancer diagnosis at assessment were excluded from this study. Our findings have important and immediate implications for clinical practice and research.

Given the prognostic significance of weight loss, we propose that assessing weight change should be an essential part of the clinical assessment (both through history and examination) of the patient with COPD and incorporated explicitly into international guidance. Although most COPD guidelines acknowledge that malnourished patients may benefit from nutritional supplementation, the need for routine nutritional screening is not always reinforced, including in GOLD guidelines. Others, for example, the latest iteration of the UK National Institute of Clinical Excellence (NICE) guidelines for COPD, recommend annual screening and provision of nutritional supplements based on BMI. However, our data demonstrate the value of screening directed towards unintentional weight loss, and we propose that future iterations of COPD guidelines should reflect this. Weight maintenance is a potentially achievable target in COPD. For example, recent meta-analyses of nutritional support have shown small but consistent effects on weight gain in patients with COPD, particularly in those who are undernourished. Moreover, in a previous trial of nutritional therapy alone or in combination with anabolic steroid treatment, a relatively modest weight gain of >2 kg was associated with improved survival. Unintentional weight loss should also trigger more detailed clinical attention of these patients, who we show are more symptomatic, have more frequent exacerbations, and may benefit from additional specialist care to manage symptoms. Smoker and ex-smokers are also at risk of neoplasia, and clinical examination with appropriate investigations may disclose neoplasia in COPD patients with weight loss at a point where treatment outcomes are better.

There is significant interest in understanding the mechanisms underlying low muscle mass in patients with COPD. However, our study clearly demonstrates a distinct subgroup with unintentional weight loss (defined as cachexia or pre-cachexia by the ERS Task Force). Future research should differentiate between phenotypes with unintentional weight loss and those with COPD and constitutionally or long-standing low FFMI. Dynamic measures that demonstrate ongoing metabolic dysfunction are required. There are likely to be significant mechanistic differences to explain body composition abnormalities in these groups with implications for the development of anabolic agents and the identification of patient phenotypes that respond best to them.

In summary, although the prevalence of cachexia and pre-cachexia in outpatients with stable COPD is low, these phenotypes are associated with important clinical manifestations including poorer exercise tolerance and greater respiratory disability. Unintentional weight loss is independently associated with mortality risk in COPD and regular monitoring of weight should be an essential part of the clinical assessment of the patient with COPD. Our data suggest that low FFMI without concurrent weight loss may not confer the poor prognosis as previously reported for this group.

Author contributions

W.D.-C.M. and M.M. did the concept and design of the study. Acquisition of the data was made by H.Y.K., C.N., S.J., S.P., R. B., and S.K. Analysis and interpretation of the data were carried out by H.Y.K., M.M., M.I.P., P.C., and W.D.-C.M. Drafting of the manuscript was performed by H.Y.K., M.M., M.I.P., P. C., and W.D.-C.M. All authors revised the manuscript critically for important intellectual content and approved the final manuscript.
Acknowledgements

The authors are grateful for the support of the staff of the Harefield Pulmonary Rehabilitation Team at the Royal Brompton and Harefield NHS Foundation Trust. We would particularly like to thank the subjects for their participation in this study.29

Conflict of interest

The authors declare no competing interests.

Authorship statement

The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia, and Muscle.

Funding

The recruitment of the cohorts was supported by a National Institute for Health Research (NIHR) Clinician Scientist Award, a Medical Research Council (UK) New Investigator Research Grant, and a NIHR Clinical Trials Fellowship awarded to W. D.-C.M. H.Y.K. was supported by a European Respiratory Society Short Term Research Fellowship. C.M.M. was supported by a NIHR Doctoral Research Fellowship and a NIHR Clinical Trials Fellowship. S.E.J. and R.E.B. are supported by NIHR Doctoral Research Fellowships. M.M. is supported by a NIHR Career Development Fellowship (CDF-2017-10-009) and the NIHR Collaboration for Leadership in Applied Health Research and Care for South London and Cicely Saunders International. W.D.-C.M. was part funded by the NIHR Collaboration for Leadership in Applied Health Research and Care Northwest London.

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Baseline characteristics of patients with COPD without cachexia (n = 1646) classified according to the presence of low or preserved fat free mass index

References

1. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018;392:1736–1788.
2. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989;139:1435–1438.
3. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005;82:53–59.
4. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007;62:115–120.
5. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006;173:79–83.
6. Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 2015;70:213–218.
7. Guerra B, Haile SR, Lamprecht B, Ramírez AS, Martínez-Cambor P, Kaiser B, et al. Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Med 2018;16:33.
8. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793–799.
9. Cederholm T, Barazoni R, Austin P, Ballmer T, Biolo G, Ristow SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr (Edinburgh, Scotland) 2017;36:49–64.
10. Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr (Edinburgh, Scotland) 2010;29:154–159.
11. Schols AM, Ferreira IM, Franssen FM, Gosker HR, Janssens W, Muscaritoli M, et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J 2014;44:1504–1520.
12. Vandenbergh E, Van de Woestijne KP, Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis 1967;95:556–566.
13. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med 2017;195:557–582.
14. Todorovic VRC, Straton R, Ward J, Elia M. The “MUST” explanatory booklet a guide to the ‘Malnutrition Universal Screening Tool’ (‘MUST’) for adults: the British Association for Parenteral and Enteral Nutrition; 2003.
15. Steiner MC, Barton RL, Singh SJ, Morgan MD. Bedside methods versus dual energy X-ray absorptiometry for body composition

Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12463
measurement in COPD. *Eur Respir J* 2002;19:626–631.
16. Managing Adult Malnutrition.
17. Franssen FM, Rutten EP, Groenen MT, Vanfleteren LE, Wouters EF, Spruit MA. New reference values for body composition by bioelectrical impedance analysis in the general population: results from the UK Biobank. *J Am Med Dir Assoc* 2014;15:448 e1–448 e6.
18. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax* 1992;47:1019–1024.
19. Kon SS, Canavan JL, Jones SE, Nolan CM, Clark Al, Dickson MJ, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. *Lancet Respir Med* 2014;2:195–203.
20. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350:1005–1012.
21. Haverkort EB, de Haan RJ, Binnekade JM, van Bokhorst-de van der Schueren MA. Self-reporting of height and weight: valid and reliable identification of malnutrition in preoperative patients. *Am J Surg* 2012;203:700–707.
22. Engelen MP, Schols AM, Lamers RJ, Wouters EF. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. *Clin Nutr* 1999;18:275–280.
23. Collins PF, Stratton RJ, Elia M. Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Am J Clin Nutr* 2012;95:1385–1395.
24. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional supplementation in stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2012;12:CD000993. https://doi.org/10.1002/14651858.CD000993.pub3
25. Maddocks M, Lovell N, Booth S, Man WD, Higginson IJ. Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. *Lancet* (London, England) 2017;390:988–1002.
26. Rabinovich RA, Drost E, Manning JR, Dunbar DR, Diaz-Ramos M, Lakhdar R, et al. Genome-wide mRNA expression profiling in vastus lateralis of COPD patients with low and normal fat free mass index and healthy controls. *Respir Res* 2015;16:1.
27. Lewis A, Lee JY, Donaldson AV, Natanek SA, Vaidyanathan S, Man WD, et al. Increased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPD. *J Cachexia Sarcopenia Muscle* 2016;7:330–344.
28. Steiner MC, Roubenoff R, Tal-Singer R, Polkey MI. Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review. *Thorax* 2012;67:1102–1109.
29. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017. *J Cachexia Sarcopenia Muscle* 2017;8:1081–1083.